Diagnostics Firms Qiagen, BioMerieux Said to Explore Tie-Up
- Firms have been studying the merits of a potential merger
- Qiagen has been the subject of strong takeover interest
A Qiagen NV nucleic acid extraction device.
Photographer: Mauricio Palos/BloombergThis article is for subscribers only.
Molecular testing firm Qiagen NV and French rival BioMerieux are exploring a potential combination that would unite two of Europe’s biggest medical diagnostics providers, people with knowledge of the matter said.
The two companies have been studying the merits of a merger, said the people, who asked not to be identified because the discussions are private.